Advertisement

Neurological Sciences

, Volume 39, Issue 12, pp 2115–2121 | Cite as

The direct costs of multiple sclerosis—study in the Czech Republic

  • Petra Maresova
  • Martin Valis
  • Michal Novotny
  • Zbyšek Pavelek
  • Kamil Kuca
Original Article

Abstract

Background

Multiple sclerosis (MS) is a progressive autoimmune disease of the central nervous system that is often disabling and for which there is currently no cure, though disease-modifying treatment is now available. The aim of this study is to describe the current values of the direct costs of multiple sclerosis (MS) in the Czech Republic.

Methods

Attention is focused on direct medical costs. The costs were monitored in the Czech Republic among 5673 patients in the period between 2011 and 2015. These costs included complex, special and targeted visits at the neurologist, blood collection and the costs of hospitalisation. The results refer to the diagnoses according to the International Statistical Classification of Diseases and Related Health Problems. The attention is focused on MS G35 (NS; brain stem; spinal cord; disseminated; generalised).

Results

The average total direct costs per patient per year are 4838.1 €. Not every patient has to be hospitalised during the year, and not every patient has prescribed medication. According to the above data, 12% of patients are hospitalised and 55% of patients are prescribed medication. The minimum average cost per patient without medication and hospitalisation is 54.1 €.

Conclusion

Cost evaluation across countries is difficult due to the different evidence. If only selected direct costs considered in this study are compared, the absolute economics burden increases over time. The only statistically significant difference in the average price and the time spent is between 2012 and 2013, where the correlation value is 0.597.

Keywords

Neurological disease Multiple sclerosis Direct costs Czech Republic 

JEL classification

I1 I15 J14 

Notes

Funding

This study was supported by the TACR AD (University of Hradec Kralove, Faculty of Informatics and Management), by an internal project at the Faculty Informatics and Management, and by the Long-term development plan UHHK.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Not applicable

References

  1. 1.
    Trojano M, Pellegrini F, Paolicelli D et al (2006) Real-life impact of early interferon β therapy in relapsing multiple sclerosis. Ann Neurol 66:513–520CrossRefGoogle Scholar
  2. 2.
    Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Doležal T, The European Multiple Sclerosis Platform (2017) New insights into the burden and costs of multiple sclerosis in Europe: results of the Czech Republic. Mult Scler 23(2_suppl):41–52.  https://doi.org/10.1177/1352458517708117 CrossRefPubMedGoogle Scholar
  3. 3.
    Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E (2012) Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler 18(5):662–668.  https://doi.org/10.1177/1352458511424422 CrossRefPubMedGoogle Scholar
  4. 4.
    Ponzio M, Gerzeli S, Brichetto G, Bezzini D, Mancardi GL, Zaratin P, Battaglia MA (2015) Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurol Sci 36(2):227–234CrossRefPubMedGoogle Scholar
  5. 5.
    Marešová P, Zahálková V (2016) The economic burden of the care and treatment for people with Alzheimer’s disease—the outlook for the Czech Republic. Neurol Sci 37(12):1917–1922.  https://doi.org/10.1007/s10072-016-2679-6 CrossRefPubMedGoogle Scholar
  6. 6.
    Holmerova I, Hort J, Rusina R et al (2017) Costs of dementia in the Czech Republic. Eur J Health Econ 18(8):979–986CrossRefPubMedGoogle Scholar
  7. 7.
    Maresova P, Klimova B, Novotny M, Kuca K (2016) Alzheimer’s and Parkinson’s diseases: expected economic impact on Europe—a call for a uniform European strategy. JAD 53(3):1123–1133.  https://doi.org/10.3233/JAD-160484 CrossRefGoogle Scholar
  8. 8.
    Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911CrossRefPubMedGoogle Scholar
  9. 9.
    Dyment DA, Ebers GC, Sadovnick AD (2004) Genetics of multiple sclerosis. Lancet Neurol 3(92):104–110CrossRefPubMedGoogle Scholar
  10. 10.
    Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61(4):288–299CrossRefPubMedGoogle Scholar
  11. 11.
    Alonso A, Hernán MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71(2):129–135CrossRefPubMedGoogle Scholar
  12. 12.
    Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191CrossRefPubMedGoogle Scholar
  13. 13.
    Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9(5):A387–A394CrossRefPubMedGoogle Scholar
  14. 14.
    Barták M, Gavúrová B (2014) Economics and social aspects of long-term care in the context of the Czech Republic and the Slovak Republic EU membership. In: Proceedings of 12th International scientific conference: economic policy in the European Union member countries, PTS I and II, vol 2015. Ostravice, Czech Republic, pp 35–44Google Scholar
  15. 15.
    Dlouhý M, Barták M (2013) Mental health financing in six Eastern European countries 16(4):4–13Google Scholar
  16. 16.
    Marešová P, Mohelská H, Dolejš J, Kuča K (2015) Socio-economic aspects of Alzheimer’s disease. Curr Alzheimer Res 12(9):903–911CrossRefPubMedGoogle Scholar
  17. 17.
    Mohelská H, Marešová P, Vališ M, Kuča K (2015) Alzheimer disease and its treatment costs case study in the Czech. Neuropsychiatr Dis Treat 11:2349–2354PubMedGoogle Scholar
  18. 18.
    Marešová P, Mohelská H, Kuča K (2016) Social and family load of Alzheimer’s disease. Appl Econ 48(21):1936–1948CrossRefGoogle Scholar
  19. 19.
    World Health Organization (2003) Guide to producing national accounts with special applications for low-income and middle-income countries. [online] Available from: http://www.who.int/health-accounts/documentation/publication_nha_guide/en/
  20. 20.
    Drummond MF, O’Brien BJ (1997) Methods for the economic evaluation of health care programs (Oxford Medical Publications), 2nd edn. Oxford Medical PublicationGoogle Scholar
  21. 21.
    Rascati KL (2014) Essentials of pharmacoeconomics, 2nd edn. Wolters Kluwer Health/Lippincott Williams, PhiladelphiaGoogle Scholar
  22. 22.
    IMPULS Endowment Fund (2016) Regular output from the ReMuS registry. Available at: http://www.multiplesclerosis.cz/docs/160914_remus_zaverecna-zprava_2016_06_souhrnna_14_9.pdf
  23. 23.
    Department of Neurology, University Hospital Hradec Králové (2014) Available from: http://www.fnhk.cz/neuro
  24. 24.
    General Health Insurance Company (Všeobecná zdravotní pojišťovna) (2015). Annual report 2013. [online] Available from: http://www.vzp.cz/uploads/document/vzp-rocenka-2013.pdf
  25. 25.
    Hartung DM, Bourdette DN, Ahmed SH et al (2015) The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology 84(21):2185–2192.  https://doi.org/10.1212/WNL.0000000000001608 CrossRefPubMedGoogle Scholar
  26. 26.
    Torabipour A, Majdinasab N, Ghasemzadeh R et al (2014) A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in Khuzestan, Iran. Int J Prev Med 5(9):1131–1138PubMedGoogle Scholar
  27. 27.
    Von Campenhausen S, Winter Y, Rodrigues E, Silva A et al (2011) Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol 21(2):180–191CrossRefGoogle Scholar
  28. 28.
    Kobelt G, Thompson A, Berg J (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J 23(8):1123–1136CrossRefGoogle Scholar
  29. 29.
    Szmurło D, Fundament T, Ziobro M, Kruntorádová K, Doležal T, Głogowski C (2014) Costs of multiple sclerosis—extrapolation of Czech data to Polish patients. Expert Rev Pharmacoecon Outcomes Res 14(3):451–458CrossRefPubMedGoogle Scholar
  30. 30.
    Adelman G, Rane SG, Villa KF (2013) The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ 16(5):639–647CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Economics, Faculty of Informatics and ManagementUniversity of Hradec KrálovéHradec KraloveCzech Republic
  2. 2.Department of Neurology, Faculty of Medicine in Hradec KrálovéCharles University in PragueHradec KraloveCzech Republic
  3. 3.Biomedical Research CentrumUniversity Hospital Hradec KrálovéHradec KraloveCzech Republic
  4. 4.Centre of Basic and Applied Research, Faculty of Informatics and ManagementUniversity of Hradec KraloveHradec KraloveCzech Republic

Personalised recommendations